Annals of Clinical Microbiology and Antimicrobials (Mar 2019)

Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue

  • Nguyen Thi Ngoc Phuong,
  • Dao Huy Manh,
  • Shyam Prakash Dumre,
  • Shusaku Mizukami,
  • Lan Nguyen Weiss,
  • Nguyen Van Thuong,
  • Tran Thi Ngoc Ha,
  • Le Hong Phuc,
  • Tran Van An,
  • Thuan Minh Tieu,
  • Mohamed Gomaa Kamel,
  • Mostafa Ebraheem Morra,
  • Vu Thi Que Huong,
  • Nguyen Tien Huy,
  • Kenji Hirayama

DOI
https://doi.org/10.1186/s12941-019-0309-x
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Considerable progress has been made in dengue management, however the lack of appropriate predictors of severity has led to huge number of unwanted admissions mostly decided on the grounds of warning signs. Apoptosis related mediators, among others, are known to correlate with severe dengue (SD) although no predictive validity is established. The objective of this study was to investigate the association of plasma cell-free DNA (cfDNA) with SD, and evaluate its prognostic value in SD prediction at acute phase. Methods This was a hospital-based prospective cohort study conducted in Vietnam. All the recruited patients were required to be admitted to the hospital and were strictly monitored for various laboratory and clinical parameters (including progression to SD) until discharged. Plasma samples collected during acute phase (6–48 h before defervescence) were used to estimate the level of cfDNA. Results Of the 61 dengue patients, SD patients (n = 8) developed shock syndrome in 4.8 days (95% CI 3.7–5.4) after the fever onset. Plasma cfDNA levels before the defervescence of SD patients were significantly higher than the non-SD group (p = 0.0493). From the receiver operating characteristic (ROC) curve analysis, a cut-off of > 36.9 ng/mL was able to predict SD with a good sensitivity (87.5%), specificity (54.7%), and area under the curve (AUC) (0.72, 95% CI 0.55–0.88; p = 0.0493). Conclusions Taken together, these findings suggest that cfDNA could serve as a potential prognostic biomarker of SD. Studies with cfDNA kinetics and its combination with other biomarkers and clinical parameters would further improve the diagnostic ability for SD.

Keywords